

## Attachment 10: IRB Approval Documentation

### CDC Human Subjects Review Board



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service  
Centers for Disease Control  
and Prevention (CDC)

---

### Memorandum

**Date** July 25, 2016

**From** Felecia Peterson  
IRB-G Administrator, Human Research Protection Office

**Subject** Site-Restriction CDC IRB Approval of New CDC Protocol 68764, "Resilience and Transgender Youth" (Expedited)

**To** Paula Jayne  
NCHHSTP/DASH

CDC's IRB-G has reviewed the request for approval of new protocol #6876, "Resilience and Transgender Youth." The IRB determined that the study involves no greater than minimal risk to subjects. The protocol was reviewed in accordance with the expedited review process outlined in 45 CFR 46.110(b)(1), under category 7. The IRB approves the inclusion of additional protections for children involved in research, as described in 45 CFR 46 subpart D. The IRB approve the waiver of parental permission. The protocol has been approved for the maximum allowable period of one year and CDC IRB approval will expire on 7/24/2017.

If other institutions involved in this protocol are being awarded CDC funds through the CDC Procurement and Grants Office (PGO), you are required to send a copy of this IRB approval to the CDC PGO award specialist handling the award. You are also required to verify with the award specialist that the awardee has provided PGO with the required documentation and have approval to begin or continue research involving human subjects as described in this protocol.

#### COLLABORATOR/SITE RESTRICTIONS:

**Institutions that receive federal support who are engaged in human subjects research are required to obtain and provide documentation of IRB approval. CDC investigators who interact with institutions that have failed to meet these requirements are collaborating with noncompliant institutions. Study activities may not begin with the collaborators listed below until documentation indicating current IRB approval has been received by CDC's Human Research Protection Office (HRPO) and the PI has been notified by HRPO that this restriction has been lifted and study activities may begin:**

1. Need current Local IRB approval – ICF International, Atlanta, Ga.

As a reminder, the IRB must review and approve all human subjects' research protocols at intervals appropriate to the degree of risk, but not less than once per year. There is no grace period beyond one year from the last IRB approval date. It is ultimately your responsibility to submit your research protocol for continuation review and approval by the IRB along with available IRB approvals from all collaborators. Please keep this approval in your protocol file as

Page 2

proof of IRB approval and as a reminder of the expiration date. **To avoid lapses in approval of your research and the possible suspension of subject enrollment and/or termination of the protocol, please submit your continuation request along with all completed supporting documentation at least six weeks before the protocol's expiration date of 7/24/2017.**

**Any problems of a serious nature must be brought to the immediate attention of the CDC IRB, and any proposed changes to the protocol should be submitted as an amendment to the protocol for CDC IRB approval before they are implemented.**

If you have any questions, please contact your National Center Human Subjects Contact or the CDC Human Research Protection Office (404) 639-7570 or e-mail: [huma@cdc.gov](mailto:huma@cdc.gov).

cc:  
NCHHSTP HS mailbox (CDC)  
Jacquie Bertrand  
Jon Baio

ICF Human Subjects Review Board

Resilience and Transgender Youth

July 27, 2016

**Institutional Review Board**

***Agreement to Comply with Human Subject Protection Requirements***

The following project has been found by the Institutional Review Board (IRB) to be in compliance with the human subject protection requirements as specified in 45 CFR 46.

**Project Title:** Resilience and Transgender Youth

**Principal Investigator/Project Director(s):** Lisa Carver, MPH

**ICF Project Number:** 121772.1.004.00.005

**Approval Date:** July 27, 2016 (with minor edits completed)


**Next Continuous Review Date:** July 27, 2017


As the responsible principal investigator/Project Director for this project, I agree to adhere to the human subject protection procedures that were approved by the IRB and to inform the chair of the IRB when any changes are made in the approved procedures. The approved procedures include all of the following:

- Subject selection and recruitment procedures
- Data collection procedures
- Informed consent procedures
- Protection of privacy and confidentiality procedures
- Data security procedures
- Additional safeguards specified by the IRB.

If you have any questions regarding changes in procedures that are subject to IRB review, please contact the IRB Chair, Janet D. Griffith ([Janet.Griffith@icfi.com](mailto:Janet.Griffith@icfi.com)), to discuss your concerns.

Also, as the responsible principal investigator or project director, I agree to cooperate with the IRB continuous annual review(s) of this project. Several weeks prior to the next annual review date listed above, the IRB Administrator will send the IRB Project Continuous Review Form or identify where to obtain the form, to complete and submit to the IRB before the annual review date. The purposes of the IRB Project Continuous Review Form are 1) to provide the IRB with updated information on the procedures used to protect the human subjects who are involved in this project, and 2) to help the IRB determine if the project is in compliance with the requirements in 45 CFR 46.

  
(Signature)

  
(Date)

Please email an original signed copy of this form to the IRB at [IRB@icfi.com](mailto:IRB@icfi.com). A copy of the signed form should also be maintained with your study files.

(Revised-07/18/2014)



DATE: July 27, 2016

TO: Lisa Carver, MPH

FROM: Janet D. Griffith, IRB Chair

SUBJECT: Institutional Review Board (IRB) Review Forms

---

Attached are the following forms for the recent IRB review of your research project:

1. *IRB Review Findings Form*, which documents the review and approval of the project.
2. Instructions on *Reporting Adverse Events and Unanticipated Problems*, which defines unexpected adverse events and unanticipated problems and details when and how the IRB should be notified of such events and problems. **Note—any problem or incident that could be an adverse event must be reported to the IRB according to the instructions in this form. Failure to comply with the adverse event reporting requirements could result in the suspension of your right to submit studies to the IRB and/or the suspension of IRB approval of this study.**
3. *Agreement to Comply with Human Subject Protection Requirements*, which ***must be signed*** by you and returned to the IRB. By signing this form, you agree to adhere to the human subject protection procedures that were approved by the IRB and to inform the IRB chair of any changes made to the approved procedures.

The first two forms are for your files; the signed electronic copy of the third form must be sent to the IRB at [IRB@icfi.com](mailto:IRB@icfi.com) and will be kept in the IRB files. Please maintain a copy of the third form for your records. If you have any questions about these forms, please email [IRB@icfi.com](mailto:IRB@icfi.com) or contact the IRB toll-free at 877-556-2218.

**ICF International Institutional Review Board  
Reporting Adverse Events and Unanticipated Problems**

---

Federal human subject protection regulations require the principal investigator (PI) or project director (PD) of an IRB approved research study to report to the IRB any *unexpected adverse events and unanticipated problems* that occur during the conduct of the research.

What Is an Unexpected Adverse Event?

Some adverse events are expected to occur during research, while others are unexpected. An *adverse event* is considered an undesirable and unintended effect of the research occurring in study subjects or others as a result of (a) the interventions and/or interactions used in the research; or (b) the collection of identifiable private information under the research. Such events are included among the risks of participating in the research. Even though an event is unintended, we often expect that a certain number of adverse events will happen during the course of the research. For example, when conducting telephone surveys, we expect some complaints from individuals who are called. Each complaint is an adverse event and should be documented, but it is not unexpected. Research protocols should include procedures for dealing with expected adverse events (risks). An *unexpected adverse event* is one that was not anticipated in the research protocol. During the IRB review of a research study, the IRB tries to make sure that all anticipated risks have been identified and included in the informed consent form, and that there are procedures in place to minimize and address those risks.

What Is an Unanticipated Problem?

An *unanticipated problem* is considered to be any event that (a) was not expected given the nature of the research procedures and the subject population being studied; and (b) suggests that the research places subjects or others at a greater risk of harm or discomfort than was previously known or recognized. Note that it is only when both conditions (a and b) are present, that a problem is defined as *unanticipated*. Unexpected adverse events are also unanticipated problems, but there can be unanticipated problems that do not meet the definition of an unexpected adverse event.

What Must Be Reported to the IRB?

Many adverse events are anticipated possible risks of participating in the research and do not need to be reported to the IRB. For example, emotional discomfort may be a risk of participating in an interview and is identified as a risk in the informed consent form. An interview that is terminated by a subject because of emotional discomfort is an adverse event, but it is expected that some interviews will be terminated for such reasons and it should not be reported to the IRB. Only adverse events that are *unexpected* need to be reported to the IRB. If the study subject threatened suicide during the interview and suicidal ideation is not identified in the study protocol and in the informed consent as a risk of participating in the interview, the suicide threat would be an unexpected adverse event and must be reported to the IRB. Also, if the researcher anticipated that very few interviews would be terminated because of emotional discomfort, but finds that a higher number of interviews than expected are being terminated for discomfort, the risk of emotional discomfort is greater than expected and must be reported to the IRB.

Many unanticipated problems are also adverse events in that the problems are unexpected consequences of exposure to the research design and/or methods. However, there are some unanticipated problems that are not related to the research but must be reported to the IRB. For example, a field interviewer has her laptop computer stolen and the interview data are not encrypted. The study subjects have been placed at greater risk of harm from breach in confidentiality of the study. Another example of an unanticipated problem is unethical behavior on the part of a study team member when interacting with study participants or using study data. Even if an unexpected problem is not likely to happen again, it must be reported to the IRB.

Problems that do not place study subjects at increased risk of harm or discomfort do not need to be reported to the IRB. For example, the termination of employment for a field data collector because he reported administering surveys that were never administered. This problem does not have to be reported to the IRB because it did not place the study subject(s) at greater risk.